期刊
ONCOLOGY RESEARCH AND TREATMENT
卷 39, 期 7-8, 页码 461-463出版社
KARGER
DOI: 10.1159/000446759
关键词
AZD9291; Osimertinib; Intracranial; Lung cancer; Response; EGFR mutation; T790M
类别
Background: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Case Report: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma. Conclusion: These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed. (C) 2016 S. Karger GmbH, Freiburg
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据